avermectin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariztia, EV; Ashworth, A; Bansal, N; Brough, R; Christova, R; Farias, E; Frankum, J; Gil, V; Howell, L; Kwon, YJ; Leibovitch, BA; Lord, CJ; Mezei, M; Petrie, K; Sbirkov, Y; Sharma, R; Waxman, S; Yang, S; Zelent, A; Zeng, L; Zhou, MM | 1 |
1 other study(ies) available for avermectin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Topics: Animals; Antigens, CD; Antiparasitic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ivermectin; Mice; Models, Molecular; Molecular Conformation; Protein Interaction Domains and Motifs; Repressor Proteins; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |